173252-76-1

Usage

Uses

Used in Pharmaceutical Industry:
5-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one is used as a synthetic intermediate for the preparation of imidazoindenopyrazinones, which are known as AMPA and NMDA receptor antagonists. These antagonists play a crucial role in the development of medications targeting neurological disorders and conditions related to excitatory neurotransmission.
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are a type of ionotropic glutamate receptor found in the central nervous system. They are involved in various physiological processes, including synaptic plasticity and learning. Modulating these receptors can help in the treatment of conditions such as epilepsy, chronic pain, and neurodegenerative diseases.
NMDA (N-methyl-D-aspartate) receptors are another class of ionotropic glutamate receptors that are essential for synaptic plasticity, learning, and memory. They are also implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Antagonists of these receptors can potentially be used in the development of therapeutics for these conditions.

Upstream product

• 52771-21-8 3-(trifluoromethoxy)benzaldehyde 
• 179381-92-1 ethyl 3-(3-(trifluoromethoxy)phenyl)acrylate 
• 179381-93-2 ethyl 3-(3-(trifluoromethoxy)phenyl)propanoate 
• 168833-77-0 3-(3-(trifluoromethoxy)phenyl)propanoic acid 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN

The present invention provides for compounds of formula (I) wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS

Heteroaryl pyridone and aza-pyridone amide compounds of Formula (I) are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety

Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines=compounds corresponding to formula (I), wherein the various substituents have the meaning provided in the description, and pharmaceutical formulations containing these compounds and methods for producing these compounds and related pharmaceutical formulation, and to methods for treating or inhibiting pain, depression and/or anxiety states.

SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES

The invention relates to the saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines of general formula (I), to methods for producing drugs containing said compounds, to the use of saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines in the production of drugs and to methods for treating pains, depressions and/or anxiety states.